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Abstract
Objectives—To test the hypothesis that multiple constituents of the apical plasma membrane 
residing alongside the causal CF Transmembrane Conductance Regulator (CFTR) protein, 
including known cystic fibrosis (CF) modifiers SLC26A9, SLC6A14, and SLC9A3, would be 
associated with prenatal exocrine pancreatic damage as measured by newborn screened (NBS) 
IRT levels.
Study design—NBS IRT measures and genome-wide genotype data were available on 111 
subjects from Colorado, 37 subjects from Wisconsin, and 80 subjects from France. Multiple linear 
regression was used to determine whether any of eight SNPs in SLC26A9, SLC6A14 and SLC9A3 
were associated with IRT and whether other constituents of the apical plasma membrane 
contributed to IRT.
Results—In the Colorado sample, three SLC26A9 SNPs were associated with NBS IRT (min P = 
1.16 × 10−3; rs7512462), but no SLC6A14 or SLC9A3 SNPs were associated (P > 0.05). The 
rs7512462 association replicated in the Wisconsin sample (P = 0.03) but not in the French sample 
(P = 0.76). Furthermore, rs7512462 was the top ranked apical membrane constituent in the 
combined Colorado and Wisconsin sample.
Conclusions—NBS IRT is a biomarker of prenatal exocrine pancreatic disease in patients with 
CF, and a SNP in SLC26A9 accounts for significant IRT variability. This suggests SLC26A9 as a 
potential therapeutic target to ameliorate exocrine pancreatic disease.
Keywords
immunoreactive trypsinogen (trypsinogen); exocrine pancreas; Modifier genes; newborn screening 
(neonatal screening or Newborn infant screening)
Cystic fibrosis (CF), a life-shortening, autosomal recessive disorder caused by mutations in 
the CF Transmembrane Conductance Regulator (CFTR) gene1 affects multiple organs, 
including the pancreas. The CF pancreas is characterized by reduced luminal fluid secretion 
and concentrated acinar proteins that accumulate in the small ducts2, 3. Pancreatic ducts and 
acini show signs of obstruction from proteinaceous secretions in utero4, and damage 
continues in early life5. Postnatally, exocrine pancreatic tissue is replaced with fibrotic tissue 
and fat6, 7.
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CFTR genotype is correlated with pancreatic disease severity, with pancreatic insufficiency 
primarily occurring in individuals with two severe CFTR genotypes8. However individuals 
with the same CFTR genotype have variable pancreatic disease at birth9, suggesting a role 
for additional genetic contributors. Serum levels of the pancreatic enzyme precursor, 
trypsinogen, measured by an immunoreactive trypsinogen (IRT) assay, are often elevated 
near birth in infants10 with two CF-causing CFTR mutations11. Elevated IRT levels at birth 
are the primary biomarker of CF in newborn screening programs.
In individuals with CFTR genotypes associated with pancreatic insufficiency, the persistent 
IRT elevation in infancy is often followed by a progressive decline, with 95% of these 
individuals with CF having lower IRT levels than a non-CF population by age seven12. This 
is likely due to progression of pancreatic damage, reduced acinar mass, and reduced capacity 
to produce digestive enzymes such as trypsin. Thus, extrapolating backwards in an IRT-
elevated CF population, lower IRT near birth is thought to reflect more severe pancreatic 
damage13. This is supported by the findings that lower IRT levels at birth is associated with 
the CF intestinal obstruction14 meconium ileus15, and increased risk of CF-related 
diabetes13. However, explicitly evaluating this hypothesis in vivo would require human 
studies of CF pancreatic tissue.
Decline in IRT levels can be used to monitor acinar destruction postnatally and to predict the 
development of pancreatic insufficiency12, 16. Thus, IRT levels may represent a biomarker 
of exocrine pancreatic damage in CF. Measures of IRT in early infancy are heritable15, 
suggesting that NBS IRT may provide a tool to identify the genetic architecture of prenatal 
exocrine pancreatic damage in CF.
With loss of CFTR function, variation in multiple constituents of the apical plasma 
membrane contribute to the risk of meconium ileus, including 8 SNPs in three solute 
carriers, SLC26A9, SLC6A14, and SLC9A317. In this study, we asked whether the meconium 
ileus risk-alleles in SLC26A9, SLC6A14, and SLC9A3 were associated with early exocrine 
pancreatic damage as measured by NBS IRT and whether multiple apical plasma membrane 
constituents contribute to prenatal exocrine pancreatic damage.
METHODS
All subjects were part of the Colorado, Wisconsin, or French sites of the International Cystic 
Fibrosis Gene Modifier Consortium, which collected DNA and clinical data from CF 
patients. All protocols were approved by institutional review boards. All participants 
provided written informed consent.
Individuals included for analysis were of European descent, had two severe CFTR mutations 
known to confer pancreatic insufficiency, and had an NBS IRT measurement. NBS IRT 
values were measured by Children’s Hospital Denver (1982–1987) or the Colorado 
Department of Public Health and Environment (1987-current)11, the Wisconsin State 
Laboratory of Hygiene18, or regional screening laboratories in France19. All subjects at each 
site who had an NBS IRT were eligible to participate in the study.
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Quality Control (QC) and DNA Collection
Standard QC measures were performed as previously described17, 20. We did not identify 
any cryptic relatedness, sex incongruity, or non-European ancestry as determined by 
principal component analysis using Eigenstrat21. There were six sibling pairs genotyped in 
the Colorado sample, five in the Wisconsin sample, and no siblings in the French sample. 
All pairwise relationships were confirmed using identity by descent estimation in PLINK22, 
and one sibling from each pair was removed at random. The final analysis included 111 
individuals from Colorado, and two replication samples of 37 and 80 individuals from 
Wisconsin and France, respectively. Commercially available IRT kits use different 
antibodies23, and Lafont et al note that these antibodies can have different specificity for 
trypsinogen or bind to different forms of trypsinogen present in serum24. Because of this, 
IRT measurements across sites may not be comparable. Hence, each of the three samples 
was analyzed separately. Colorado was the largest sample, and was treated as the discovery 
sample, with Wisconsin and France each used as a replication sample.
DNA was extracted from whole blood or transformed lymphocytes and quantified with 
fluorimetry. DNA of the French sample was genotyped using two genotyping platforms with 
different subsets of genetic markers, the Illumina CNV 370-Duo BeadChip or the Illumina 
6620W-Quad BeadChip (660W). DNA of the Colorado and Wisconsin samples was 
genotyped simultaneously using the 660W. Individuals from Colorado or Wisconsin with 
missing genotype rate >2% (n = 22) were re-genotyped on the Illumina Omni5-Quad 
BeadChip (Omni5). There were 431,504 SNPs on the 660W and Omni5 that overlapped and 
passed QC.
Genotype imputation uses a reference set of population haplotypes to infer un-typed 
genotypes in a sample of interest. We used MaCH and Minimac25 to impute the 22 
individuals genotyped on the Omni5 at 79,159 SNPs unique to the 660W, and all French 
samples to the SNPs on the 660W (Figure 1; available at www.jpeds.com). SLC9A3 SNP 
rs17563161 was not present on either genotyping platform, and genotype calls for this SNP 
were imputed in the full sample. Imputed SNPs were required to have R2 > 0.3 and minor 
allele frequency ≥ 5.0%.
NBS IRT Measurement and Assay
NBS for CF has been in place in Colorado since 198211. In Wisconsin NBS for CF was 
available as a clinical trial from 1985 to 199426, and available to all infants after 199418. 
Nationwide NBS has been in place in France since 200219, but previously existed in 
Normandy (1980)27 and Brittany (1989)28. In Colorado and Wisconsin, IRT is measured by 
a single state laboratory; in France, it is measured at one of 22 regional laboratories19. In all 
three locations, newborn infants’ blood is collected via a heel stick and placed on filter 
cards. IRT is extracted and measured from the dried blood spots.
The assays used to measure IRT have changed during the course of NBS at all three sites 
(Figure 2; available at www.jpeds.com). Additional details of the assays and changes are 
published elsewhere11, 18, 19, 27, 29. The assay used in France until 2002 required all 
newborn infants with IRT ≥ 900 ng/ml undergo follow-up testing for CF. The IRT assay 
Miller et al. Page 4













changed in 2002, and the new assay had a positive CF-screening value of 60 ng/ml. In 
France, IRT values from the older assay are divided by 15 in order to make them 
comparable with values from the new assay.
Statistical Analyses
All analyses were conducted using R30. Kruskal-Wallis tests were used to determine if IRT 
varied by assay in any of the sites, varied between sites, or varied with other covariates of 
interest. We used Spearman’s correlation to test for a correlation between IRT and age of 
IRT measurement. Chi-square tests were used to determine if descriptive characteristics (i.e. 
sex, meconium ileus) varied significantly (P < 0.05) by site.
In the Colorado sample, 8 SNPs were tested for associations with IRT individually using 
multiple linear regression. SNPs were coded additively as 0, 1, or 2, corresponding to the 
number of risk alleles defined by meconium ileus findings17. For chromosome X SNPs, 
males were coded as 0 or 2. Regression models for each SNP were adjusted for each of the 
following covariates separately: meconium ileus status, sex, CFTR genotype (delF508 
homozygotes versus all others), IRT assay, and population structure using principal 
components. Inclusion of these covariates did not impact the results, and unadjusted results 
are presented, with adjusted results for the most significantly associated SNP presented in 
Tables V and VI (available at www.jpeds.com). The effective number of independent tests 
across the 8 SNPs was estimated as 6 using the Genetics Type I Error Calculator software, 
which takes into account correlation between markers31. To adjust for multiple hypothesis 
testing, we required a significance level of α = 0.0083 (0.05/6) to conclude statistical 
significance.
We assessed the evidence for replication of a SNP-IRT association identified in the 
Colorado sample, using the Wisconsin and French samples. We used the same statistical 
models and required the same risk allele to be associated, although all reported p-values are 
two-sided.
To determine if IRT has a complex genetic inheritance with multiple constituents of the 
apical plasma membrane contributing to pancreatic damage, we conducted a gene-set 
analysis of the apical constituents and a single-SNP analysis to assess significance at the 
individual markers annotated to the gene-set. As in the report by Sun et al17, a list of 157 
genes that localize to the apical plasma membrane was identified. Because the majority of 
the study participants were genotyped on the 660W, we limited analysis to SNPs on this 
platform that passed QC with a minor allele frequency ≥ 2.0%. The distribution of IRT was 
similar between Colorado and Wisconsin (P = 0.57); thus the two samples were combined (n 
= 148) for the gene-set analysis with 3,614 SNPs. We repeated the gene-set analysis in the 
French sample (3,567 SNPs). We used permutation analysis to assess statistical significance 
of the Wald Chi-squared sum statistic across the 3,614 SNPs (Colorado and Wisconsin) or 
3,567 SNPs (France) in the gene-set.
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The three samples are described in Table I. In France, all NBS blood samples were collected 
at three days of age, whereas in Colorado and Wisconsin the timing of the blood collection 
varied. The three sites are comparable in distribution of sex, percent with meconium ileus, 
and occurrence of delF508 mutations. IRT distribution does not differ between Colorado and 
Wisconsin, but is lower in France (P < 0.0001) than either North American sample (Figure 
3; available at www.jpeds.com).
IRT does not vary by sex or CFTR genotype () in any of the three sites. IRT values are not 
correlated with age at IRT measurement (Colorado and Wisconsin; Figure 4 available at 
www.jpeds.com). In Wisconsin, IRT levels were greater when measured with the radio-
immunoassay than the time-resolved fluorometric assay (P = 0.008; Figure 4). IRT is similar 
by assay in Colorado and France. IRT is lower in individuals with meconium ileus 
(Colorado: P = 0.002; Wisconsin: P = 0.03), though this does not reach statistical 
significance in the French sample (P = 0.09; Figure 4).
In the Colorado sample, three SNPs in SLC26A9 were associated with NBS IRT (min P = 
1.16 × 10−3 at rs7512462; Table II). No SNPs in SLC9A3 (P = 0.50) or SLC6A14 (min P = 
0.21) showed evidence of association (Table II). Each additional copy of the rs7512462 
meconium ileus risk allele17 was associated with lower NBS IRT (i.e. worse pancreatic 
disease) of 49 ng/ml (95% Confidence Interval (CI): (−78, −20)); this SNP explained 9% of 
the variability in NBS IRT. The distribution of IRT by number of rs7512462 risk alleles is 
presented in Figure 4. Limiting the analysis to individuals homozygous for the CFTR 
delF508 mutation (n = 62) resulted in similar findings (P = 6.65 × 10−3; β = −50 ng/ml). The 
three associated SNPs in SLC26A9 are in reasonably high linkage disequilibrium (Figure 
5).32 After adjusting for the effect of rs7512462, the other SNPs were no longer associated 
(P = 0.45 and 0.19 for rs4077468 and rs12047830, respectively) suggesting the three SNPs 
tag the same underlying genetic cause.
In the Wisconsin sample, rs7512462 was significantly associated with NBS IRT (P = 0.03, β 
= −57 ng/ml, 95% CI: −108, −6; Table III) and explained ~13% of the variability in IRT. 
Evidence for association was similar in the delF508 homozygous group (n = 27; p = 0.023; β 
= −66 ng/ml). There was no evidence that rs7512462 contributed to variability in the French 
measure of NBS IRT (P = 0.76, β = 3 ng/ml, 95% CI: (−18, 24)), and this was similar when 
limiting to the delF508 homozygous group (n = 52, p = 0.76, β = 4 ng/ml). When the two 
North American samples were combined, evidence for association between NBS IRT and 
rs7512462 was similar to the site specific samples (P = 6.77 × 10−5; β = −51 ng/ml, 95% CI: 
(−76, −26)); rs7512462 explained ~10% of the variance in IRT. Evidence for association 
was similar in the delF508 homozygous group (n = 89, p = 6.65 × 10−3, β = −55 ng/ml). 
Covariate adjustment did not impact these results (Tables IV and V; Table IV available at 
www.jpeds.com). Imputation of the SLC26A9 region did not identify any additional SNPs 
that were more strongly associated with NBS IRT than rs7512462 (Figure 5).
We did not find significant evidence of a complex genetic architecture for exocrine 
pancreatic disease as measured by NBS IRT, with multiple constituents of the apical plasma 
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membrane contributing to early exocrine pancreatic damage (p = 0.26; Figure 6 available at 
www.jpeds.com). Further, when we examine the association evidence from the individuals 
SNPs in this group, rs7512462 in SLC26A9 is the top ranked SNP (Table VI) with no other 
SNP reaching an experiment-wise (0.05/3614 = 1.38 × 10−5) significance level.
Similarly, in the French sample, we did not find any evidence that multiple constituents 
contributed to early exocrine pancreatic damage (P = 0.46; Figure 6), and there are no 
individual SNPs annotated to the 155 genes that reach experiment-wise significance (Table 
VII; available at www.jpeds.com).
DISCUSSION
We found a strong association between SLC26A9 rs7512462 and prenatal exocrine 
pancreatic disease in a sample of individuals with CF from Colorado. This association 
replicated in a sample of individuals with CF from Wisconsin, but not in a sample from 
France. In both the Colorado and Wisconsin samples, the rs7512462 meconium ileus risk 
allele was associated with more severe pancreatic disease, as indicated by a lower newborn 
screened IRT value; provided similar effect size estimates; and accounted for a similar and 
substantial amount of the variability in NBS IRT. We did not find any SNPs in SLC6A14 or 
SLC9A3 that were associated with early exocrine pancreatic disease severity. This supports 
previous findings that SLC6A14 and SLC9A3 are associated with CF pulmonary phenotypes, 
but not pancreatic phenotypes33, and is consistent with known expression data. Based upon 
a study of human adult tissues34, SLC9A3 is abundantly expressed in kidney and small 
intestine, and SLC6A14 is abundantly expressed in human lung and salivary gland. Lohi et al 
report expression of SLC26A9 in the human pancreas35. Pancreatic expression was not 
reported in a study of adult human tissues34, although the importance of SLC26A9 function 
in the gastrointestinal tract of very young mice has been reported36. SLC26A9 encodes an 
anion transporter that can mediate chloride-bicarbonate exchange and sodium-coupled 
transport37. It can physically interact with CFTR and be influenced by CFTR activity38, 39. 
In CF, with the loss of CFTR function at the apical plasma membrane, SLC26A9 may 
augment ion transport and fluid flow, explaining its modifying effect. From a clinical 
perspective, individuals diagnosed with CF through newborn screening could be screened 
for rs7512462. Individuals who carry the risk allele may have worse pancreatic damage and 
could be monitored more closely for failure to thrive and the need to start enzyme treatments 
sooner.
We were unable to find evidence of a complex genetic model for CF exocrine pancreatic 
disease with multiple apical constituents contributing to NBS IRT, unlike for other CF 
comorbidities such as meconium ileus and lung disease17, 33. However, for other CF 
comorbidities, individual associated SNPs accounted for much less than 10% of trait 
variability, which is consistent with a complex inheritance model.
Multiple factors could explain the lack of association with rs7512462 in the French sample. 
It is possible that a different constituent of the apical plasma membrane contributes to 
exocrine pancreatic damage in the French sample, and we were underpowered to detect this. 
Another explanation is that the French sample differed fundamentally from the American 
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samples. IRT was assayed at one of 22 regional laboratories in France, whereas the 
Wisconsin and Colorado sites each have centralized measurements of IRT, introducing more 
heterogeneity in the French sample. Moreover, different commercial IRT kits use different 
antibodies23, which have different specificity for trypsinogen or bind to different forms of 
trypsinogen present in serum24. Further, there is no certified IRT reference material, so the 
IRT provided as a reference can vary in level in different kits40. Finally, the stability of IRT 
measured from blood spots may be affected by transport time from the hospital to the testing 
facility and the climate of the area41. All of these factors could affect the IRT levels 
measured in the French sample, leading to the observed difference in IRT distribution across 
the samples and the lack of rs7512462 association. We were unable to link the specific 
laboratory corresponding to individual IRT measurements in the French data to determine if 
the IRT values differed by site.
A limitation of this study is the relatively small sample size available, which precluded 
interrogation of the whole genome for markers associated with prenatal exocrine pancreatic 
damage. However, the observed difference in IRT distribution between the French and 
American samples provide a note of caution for future studies that may wish to use the NBS 
IRT values from multiple sites/laboratories in order to increase their sample sizes. Not all 
CF IRT-based newborn screening protocols result in equally interpretable biomarkers. A 
second limitation is that the study was restricted to individuals of European ancestry, and 
therefore our results only generalize to that population.
Despite changes to the assay, the ratio of signal to noise was strong enough that we were 
able to use the NBS IRT value from the Colorado and Wisconsin samples as a biomarker to 
reflect prenatal exocrine pancreatic disease severity in CF and identify a gene modifier, 
suggesting that NBS IRT has utility beyond a threshold for determining CF. Further 
investigation is required to disentangle which assays may be more or less useful for this 
purpose outside of those considered here.
Prenatal exocrine pancreatic damage in CF is influenced by the solute carrier SLC26A9 with 
one SNP in this gene accounting for a substantial percentage of the variability in NBS IRT. 
The robust finding that SLC26A9 is a CF gene modifier and a marker of CF pancreatic 
disease severity suggests a potential therapeutic target to slow the progression of exocrine 
pancreatic damage in CF.
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Methodology for combining genotypes for individuals from Colorado and Wisconsin 
genotyped on the Illumina 660W-Quad BeadChip and re-genotyped on the Illumina Omni5-
Quad BeadChip. Standard quality control was performed on all genotypes.
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Changes to the IRT assay over time in each site. The x-axis represents year of measurement, 
and each box indicated the type of assay used, including the (1) assay name, (2) 
manufacturer, (3) type of assay, and (4) percent of subjects in each site that used that assay.
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Distribution of NBS IRT in Colorado, Wisconsin and French samples. Box represents 25th, 
50th (median), and 75th percentile. Whiskers represent 5th and 95th percentiles, and open 
circles represent values above the 95th percentile.
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Distribution of NBS IRT is compared, within each site, by the following variables of 
interest: Sex (row 1): males versus female. CFTR mutation (row 2): Subjects are classified as 
delF508 homozygotes (DFDF) versus all others. Age at IRT (row 3): Correlation of age at 
IRT with IRT value (Colorado and Wisconsin only; In France, IRT is measured at 3 days of 
age). Assay (row 4): Categorized by the technology used to measure IRT, either radio-
immunoassay (RIA), or a time-resolved fluorometric assay (FIA). Meconium ileus status 
(row 5): subjects with meconium ileus (MI) versus those without MI. Total n may be 
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reduced as some subjects are missing MI status. Number of rs7512462 risk alleles (row 6): 
0, 1, or 2 risk alleles. P-values for sex, assay, MI status and CFTR determined using 
Kruskal-Wallis tests. P-value for rs7512462 determined using linear regression. Age at IRT 
correlation determined using Spearman’s correlation. Box represents 25th, 50th (median), 
and 75th percentile. Whiskers represent 5th and 95th percentiles, and open circles represent 
values above the 95th percentile.
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Regional plot for SLC26A9 in the combined Colorado and Wisconsin sample. LocusZoom 
viewer32 was used to show association evidence around SLC26A9 based on human genome 
build 19. Symbol coloring represents LD r2 values of the 1000 genomes European sample 
with the most significant SNP.
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There is no evidence of association between NBS IRT and the apical plasma membrane 
constituents in the Colorado and Wisconsin samples (n = 148) or in the French samples (n = 
80). As in Sun et al.17, a list of 157 genes that localize to the apical plasma membrane was 
identified. We included 3,614 SNPs (Colorado and Wisconsin) or 3,567 SNPs (French) from 
the Illumina 660W-Quad BeadChip with minor allele frequency >2% that were annotated to 
+/−10 kb of the boundaries of the 155 genes. Two genes were not tagged by any GWAS 
SNPs. (A) Quantile-quantile plot in the combined Colorado and Wisconsin samples. The 
observed association statistics (black dotted line) and the statistics calculated from 10,000 
IRT permuted replicates (gray) are shown. (B) Statistical significance of the apical plasma 
membrane hypothesis in the combined Colorado and Wisconsin samples. P-value (0.26) was 
established via a statistic that summed over the association evidence (Wald chi-squared 
statistic) of all the 3,614 SNPs with the observed sum statistic shown as a vertical line 
(black) and 10,000 permutation-based sum statistics shown as a histogram. (C) Quantile-
quantile plot in the French replication sample. (D) Statistical significance of the apical 
membrane hypothesis in the French replication sample (P = 0.46).
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Table 1








IRT, ng/ml, mean (SD) 255 (116) 236 (101) 151 (68)
Age at IRT measurement, days, median (IQR) 2 (1–3) 3 (2–4) 3 (NA)a
Year of birth, range 1983–2008 1986–2006 1981–2006
Male, n (%) 46 (41) 21 (57) 41 (51)
Meconium ileus positive, n (%) 23 (22)b 9 (24) 14 (18)c
Number p.Phe508del mutations, n (%)d
 0 4 (4) 1 (3) 3 (4)
 1 45 (41) 9 (24) 24 (30)
 2 62 (56) 27 (73) 53 (66)
SD, standard deviation; IQR, inter-quartile range
a
: All blood samples are drawn at 3 days of age in this sample
b
: Based on a sample size of 103; 8 subjects missing meconium ileus status.
c
: Based on a sample size of 76; 4 subjects missing meconium ileus status.
d
: Cells may not sum to 100% due to rounding.
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Table 4
Covariate adjustment for association of SLC26A9 SNP rs7512462 with NBS IRT in the Colorado and 
Wisconsin combined samples (n = 148).
Covariate in Model pSNP βSNP (95% CI) pcovariate R2 model
None (rs7512462 only) 6.77 × 10−5 −51 (−76, −26) N/A 0.10
Sex 7.30 × 10−5 −51 (−76, −26) 0.72 0.10
CFTRa 2.02 × 10−5 −56 (−80, −31) 0.06 0.13
Age at IRT measurement (days) 1.56 × 10−4 −51 (−77, −25) 0.95 0.10
IRT assay 4.85 × 10−5 −52 (−77, −28) 0.16 0.12
Meconium ileusb 1.37 × 10−4 −48 (−72, −24) 1.90 × 10−4 0.19
Principal componentsc 2.32 × 10−5 −56 (−81, −31) 0.15 0.13
Site 9.87 × 10−5 −51 (−77, −25) 0.74 0.10
a
: Subjects are classified as delF508 homozygotes versus all other mutations.
b
: Based on a total sample of 140; 8 subjects are missing Meconium ileus status.
c
: Adjusted for population structure, based on the first four principal components.
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Table 5
Covariate adjustment for association of rs7512462 with NBS IRT in the French sample (n = 80).
Covariate in Model pSNP βSNP (95% CI) pcovariate R2 model
None (rs7512462 only) 0.76 3 (−18, 24) NA 0.00
Sex 0.78 3 (−18, 24) 0.35 0.01
CFTRa 0.72 4 (−18, 25) 0.58 0.01
IRT assay 0.67 5 (−17, 26) 0.38 0.02
Meconium ileusb 0.83 3 (−20, 25) 0.33 0.01
Principal componentsc 0.83 2 (−19, 24) 0.64 0.06
a
: Subjects are classified as delF508 homozygotes versus all other mutations.
b
: Based on a total sample of 140; 8 subjects are missing Meconium ileus status.
c
: Adjusted for population structure, based on the first four principal components.
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Table 6
Top ranked apical plasma membrane constituents in the combined Colorado and Wisconsin samples (n = 148).
SNP Chromosome Positiona P value Gene
rs7512462 1 205899595 6.77 × 10−5 SLC26A9
rs242050 1 4789179 3.72 × 10−4 AJAP1
rs12047830 1 205916699 7.61 × 10−4 SLC26A9
rs7415921 1 205910883 8.80 × 10−4 SLC26A9
rs7232775 18 43202404 1.42 × 10−3 SLC14A2
rs9675236 17 58226800 1.70 × 10−3 CA4
rs4077468 1 205914757 2.24 × 10−3 SLC26A9
rs4077469 1 205914885 2.24 × 10−3 SLC26A9
rs2627907 17 58218881 2.63 × 10−3 CA4
rs1321507 6 51826281 3.41× 10−3 PKHD1
a
: Based on Genome Reference Consortium Human Reference 37/Human Genome 19.













Miller et al. Page 25
Table 7
Top ranked apical plasma membrane constituents in the French sample (n = 80).
SNP Chromosome Positiona P value Gene
rs35806 10 79165830 6.58 × 10−4 KCNMA1
rs776385 8 31736625 1.88 × 10−3 NRG1
rs4458837 8 32304383 1.90 × 10−3 NRG1
rs1425802 11 35158401 1.96 × 10−3 CD44
rs673195 10 79164857 2.61 × 10−3 KCNMA1
rs11802794 1 197372250 2.95 × 10−3 CRB1
rs353625 11 35168546 3.45 × 10−3 CD44
rs6718187 2 44082362 4.69 × 10−3 ABCG8
rs4148179 2 44056856 4.72 × 10−3 ABCG5
rs4148178 2 44057030 4.72 × 10−3 ABCG5
a
: Based on Genome Reference Consortium Human Reference 37/Human Genome 19.
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